William Kaelin Jr.

William Kaelin Jr.'s AcademicInfluence.com Rankings

William Kaelin Jr.

Philosophy

#3402

World Rank

#5512

Historical Rank

#1085

USA Rank

Logic

#1181

World Rank

#1865

Historical Rank

#371

USA Rank

philosophy Degrees

Download Badge

Philosophy

Why Is William Kaelin Jr. Influential?

(Suggest an Edit or Addition)

According to Wikipedia, William G. Kaelin Jr. is an American Nobel laureate physician-scientist. He is a professor of medicine at Harvard University and the Dana–Farber Cancer Institute. His laboratory studies tumor suppressor proteins. In 2016, Kaelin received the Albert Lasker Award for Basic Medical Research and the AACR Princess Takamatsu Award. He also won the Nobel Prize in Physiology or Medicine in 2019 along with Peter J. Ratcliffe and Gregg L. Semenza.

(See a Problem?)

William Kaelin Jr.'s Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing (2001) (4358)
Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. (2008) (2636)
Comprehensive molecular characterization of clear cell renal cell carcinoma (2013) (1724)
Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein (2000) (1551)
The Concept of Synthetic Lethality in the Context of Anticancer Therapy (2005) (1349)
Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. (2004) (1307)
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins (2014) (1044)
The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage (1999) (948)
p73 is a human p53-related protein that can induce apoptosis (1997) (940)
Role of VHL gene mutation in human cancer. (2004) (937)
Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. (1996) (883)
E2F-1 Functions in Mice to Promote Apoptosis and Suppress Proliferation (1996) (858)
Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. (1994) (846)
Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. (1999) (823)
Molecular basis of the VHL hereditary cancer syndrome (2002) (806)
Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties (1992) (799)
Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. (1999) (786)
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma (2018) (772)
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. (2002) (765)
Tumour suppression by the human von Hippel-Lindau gene product (1995) (717)
Influence of Metabolism on Epigenetics and Disease (2013) (705)
Role for the p53 homologue p73 in E2F-1-induced apoptosis (2000) (674)
Transformation by the R Enantiomer of 2-Hydroxyglutarate Linked to EglN Activation (2012) (663)
The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer (2008) (649)
(R)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible (2013) (637)
The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. (1998) (626)
Inhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor Growth (2003) (592)
Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor (2002) (561)
Structure of an HIF-1α-pVHL Complex: Hydroxyproline Recognition in Signaling (2002) (556)
A common polymorphism acts as an intragenic modifier of mutant p53 behaviour (2000) (544)
Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. (2005) (527)
TSC2 regulates VEGF through mTOR-dependent and -independent pathways. (2003) (519)
Negative regulation of the growth-promoting transcription factor E2F-1 by a stably bound cyclin A-dependent protein kinase (1994) (515)
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. (2013) (506)
Identification of cellular proteins that can interact specifically with the T/ElA-binding region of the retinoblastoma gene product (1991) (505)
Suppression of tumor growth through disruption of hypoxia-inducible transcription (2000) (503)
Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex. (2001) (502)
Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-promoting complex (2004) (493)
The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. (1998) (467)
Identification of a growth suppression domain within the retinoblastoma gene product. (1992) (442)
Proline hydroxylation and gene expression. (2005) (436)
The Retinoblastoma Binding Protein RBP2 Is an H3K4 Demethylase (2007) (432)
Chemosensitivity linked to p73 function. (2003) (431)
The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. (2005) (417)
Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. (2009) (392)
Regulation of Hypoxia-Inducible mRNAs by the von Hippel-Lindau Tumor Suppressor Protein Requires Binding to Complexes Containing Elongins B/C and Cul2 (1998) (388)
Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors (1996) (382)
von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. (2001) (368)
Stable binding to E2F is not required for the retinoblastoma protein to activate transcription, promote differentiation, and suppress tumor cell growth. (1998) (366)
A common E2F-1 and p73 pathway mediates cell death induced by TCR activation (2000) (362)
E2F-1-mediated transactivation is inhibited by complex formation with the retinoblastoma susceptibility gene product. (1993) (357)
Genetic and functional studies implicate HIF1α as a 14q kidney cancer suppressor gene. (2011) (356)
MDM2 Suppresses p73 Function without Promoting p73 Degradation (1999) (351)
p73 is a simian [correction of human] p53-related protein that can induce apoptosis. (1997) (339)
A protein synthesis-dependent increase in E2F1 mRNA correlates with growth regulation of the dihydrofolate reductase promoter (1993) (337)
The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. (2008) (330)
HIF hydroxylation and the mammalian oxygen-sensing pathway. (2003) (326)
A genetic mechanism for Tibetan high-altitude adaptation (2014) (321)
Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. (1999) (321)
On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models (2016) (313)
The T/E1A-binding domain of the retinoblastoma product can interact selectively with a sequence-specific DNA-binding protein (1991) (312)
The von Hippel-Lindau Tumor Suppressor Protein and Clear Cell Renal Carcinoma (2007) (312)
The von Hippel-Lindau tumor suppressor gene. (2001) (309)
The VHL/HIF axis in clear cell renal carcinoma. (2013) (307)
The Von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer (2004) (303)
Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion (2011) (298)
Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production. (2006) (294)
Transcription of the E2F-1 gene is rendered cell cycle dependent by E2F DNA-binding sites within its promoter (1994) (293)
The von Hippel-Lindau tumor suppressor protein. (2001) (280)
Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. (2008) (273)
Role of the retinoblastoma protein in the pathogenesis of human cancer. (1997) (271)
A potent transrepression domain in the retinoblastoma protein induces a cell cycle arrest when bound to E2F sites. (1995) (269)
p53 family update: p73 and p63 develop their own identities. (2001) (265)
pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. (1998) (259)
VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400 (2008) (247)
A maize cDNA encoding a member of the retinoblastoma protein family: involvement in endoreduplication. (1996) (241)
Binding of pRB to the PHD protein RBP2 promotes cellular differentiation. (2005) (232)
The VHL tumour-suppressor gene paradigm. (1998) (227)
Fumarate and Succinate Regulate Expression of Hypoxia-inducible Genes via TET Enzymes* (2015) (220)
Functions of the retinoblastoma protein. (1999) (219)
Regulation of the Ets-related transcription factor Elf-1 by binding to the retinoblastoma protein. (1993) (212)
The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing. (2005) (211)
Viral Oncoproteins Discriminate between p53 and the p53 Homolog p73 (1998) (211)
Histone demethylase KDM6A directly senses oxygen to control chromatin and cell fate (2019) (209)
Definition of the minimal simian virus 40 large T antigen- and adenovirus E1A-binding domain in the retinoblastoma gene product (1990) (208)
The von Hippel-Lindau Tumor Suppressor Gene Inhibits Hepatocyte Growth Factor/Scatter Factor-Induced Invasion and Branching Morphogenesis in Renal Carcinoma Cells (1999) (204)
The transcription factor E2F-1 is a downstream target of RB action (1995) (204)
Myc-enhanced expression of Cul1 promotes ubiquitin-dependent proteolysis and cell cycle progression. (2000) (203)
Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. (2004) (203)
Q&A: Cancer: Clues from cell metabolism (2010) (200)
Failure to prolyl hydroxylate hypoxia‐inducible factor α phenocopies VHL inactivation in vivo (2006) (197)
Retinoblastoma Protein Contains a C-terminal Motif That Targets It for Phosphorylation by Cyclin-cdk Complexes (1999) (193)
Phosphorylation by casein kinase I promotes the turnover of the Mdm2 oncoprotein via the SCF(beta-TRCP) ubiquitin ligase. (2010) (193)
An intact NEDD8 pathway is required for Cullin‐dependent ubiquitylation in mammalian cells (2002) (188)
pVHL Modification by NEDD8 Is Required for Fibronectin Matrix Assembly and Suppression of Tumor Development (2004) (186)
Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma (2018) (183)
The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer. (2003) (183)
The p53 gene family (1999) (183)
RBP1 Recruits Both Histone Deacetylase-Dependent and -Independent Repression Activities to Retinoblastoma Family Proteins (1999) (182)
The Hypoxia-Inducible Factor 2α N-Terminal and C-Terminal Transactivation Domains Cooperate To Promote Renal Tumorigenesis In Vivo (2007) (181)
pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2. (2007) (180)
Retinoblastoma protein and anaphase-promoting complex physically interact and functionally cooperate during cell-cycle exit (2007) (172)
Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector (1997) (170)
Targeting the HIF2–VEGF axis in renal cell carcinoma (2020) (167)
ROS: really involved in oxygen sensing. (2005) (165)
How oxygen makes its presence felt. (2002) (160)
Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine (2016) (160)
Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes. (2004) (159)
Use and Abuse of RNAi to Study Mammalian Gene Function (2012) (159)
The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. (2003) (159)
The emerging p53 gene family. (1999) (154)
Reactivation of Hepatic EPO Synthesis in Mice After PHD Loss (2010) (154)
The EGLN-HIF O2-Sensing System: Multiple Inputs and Feedbacks. (2017) (151)
Cancer and altered metabolism: potential importance of hypoxia-inducible factor and 2-oxoglutarate-dependent dioxygenases. (2011) (149)
A Feedback Loop Involving the Phd3 Prolyl Hydroxylase Tunes the Mammalian Hypoxic Response In Vivo (2009) (148)
Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo. (2006) (147)
Kinase requirements in human cells: III. Altered kinase requirements in VHL−/− cancer cells detected in a pilot synthetic lethal screen (2008) (147)
pVHL suppresses kinase activity of Akt in a proline-hydroxylation–dependent manner (2016) (144)
Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1 (2011) (143)
Von Hippel-Lindau disease. (1997) (143)
Transcriptional control by E2F. (1995) (142)
SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer. (2013) (137)
A phase I study of cabozantinib (XL184) in patients with renal cell cancer. (2014) (137)
FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal tumorigenesis. (2010) (137)
Expression pattern of the von Hippel-Lindau protein in human tissues. (1996) (135)
Loss of Hypoxia-Inducible Factor Prolyl Hydroxylase Activity in Cardiomyocytes Phenocopies Ischemic Cardiomyopathy (2010) (130)
Gene expression profiling in a renal cell carcinoma cell line: dissecting VHL and hypoxia-dependent pathways. (2003) (127)
HIF2α cooperates with RAS to promote lung tumorigenesis in mice (Journal of Clinical Investigation (2009) 119, (2160-2170) doi:101172/JCI38443) (2009) (126)
Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. (2009) (125)
The cellular effects of E2F overexpression. (1996) (124)
Common pitfalls in preclinical cancer target validation (2017) (122)
Rapid and durable recovery of visual function in a patient with von hippel-lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416. (2002) (121)
A role for mammalian Sin3 in permanent gene silencing. (2008) (120)
Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues. (1997) (118)
The von Hippel-Lindau gene, kidney cancer, and oxygen sensing. (2003) (118)
Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate (2015) (118)
Mouse reporter strain for noninvasive bioluminescent imaging of cells that have undergone Cre-mediated recombination. (2003) (117)
CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer. (2019) (109)
Hypoxia-Inducible Factor Linked to Differential Kidney Cancer Risk Seen with Type 2A and Type 2B VHL Mutations (2007) (108)
Cloning, chromosomal location, and characterization of mouse E2F1 (1994) (107)
Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein. (1999) (106)
Prolyl hydroxylation by EglN2 destabilizes FOXO3a by blocking its interaction with the USP9x deubiquitinase (2014) (106)
Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL−/− clear cell renal carcinoma (2017) (106)
Treatment of kidney cancer (2009) (105)
Cells Degrade a Novel Inhibitor of Differentiation with E1A-Like Properties upon Exiting the Cell Cycle (2000) (105)
HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice. (2009) (102)
VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma (2018) (102)
PHD3 Loss in Cancer Enables Metabolic Reliance on Fatty Acid Oxidation via Deactivation of ACC2. (2016) (101)
von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids. (1998) (98)
Cells Lacking the RB1 Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival. (2018) (96)
Synthetic lethality: a framework for the development of wiser cancer therapeutics (2009) (93)
Bioluminescent imaging of Cdk2 inhibition in vivo (2004) (91)
Role of the newer p53 family proteins in malignancy (2001) (90)
The von Hippel-Lindau tumour suppressor protein: new perspectives. (1999) (87)
Diverse Effects of Mutations in Exon II of the von Hippel-Lindau (VHL) Tumor Suppressor Gene on the Interaction of pVHL with the Cytosolic Chaperonin and pVHL-Dependent Ubiquitin Ligase Activity (2002) (85)
Deubiquitinases Maintain Protein Homeostasis and Survival of Cancer Cells upon Glutathione Depletion. (2019) (83)
Human cytotrophoblast expression of the von Hippel-Lindau protein is downregulated during uterine invasion in situ and upregulated by hypoxia in vitro. (2001) (81)
Pyomyositis in patients with diabetes mellitus. (1991) (80)
EGLN1 Inhibition and Rerouting of α-Ketoglutarate Suffice for Remote Ischemic Protection (2016) (79)
p63 and p73: old members of a new family. (2000) (78)
Preferential retention of codon 72 arginine p53 in squamous cell carcinomas of the vulva occurs in cancers positive and negative for human papillomavirus. (2000) (76)
Molecular pathways in renal cell carcinoma--rationale for targeted treatment. (2006) (74)
The VHL Tumor Suppressor Gene: Insights into Oxygen Sensing and Cancer. (2017) (73)
Third International Meeting on von Hippel-Lindau disease. (1999) (72)
SDH5 mutations and familial paraganglioma: somewhere Warburg is smiling. (2009) (70)
Effect of verapamil on malignant tissue blood flow in SMT-2A tumor-bearing rats. (1982) (70)
Coordinated repression of cell cycle genes by KDM5A and E2F4 during differentiation (2012) (69)
Phosphorylation of ETS1 by Src family kinases prevents its recognition by the COP1 tumor suppressor. (2014) (68)
Choosing anticancer drug targets in the postgenomic era. (1999) (68)
D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice (2014) (68)
2-Oxoglutarate-dependent dioxygenases in cancer (2020) (68)
Faculty Opinions recommendation of Cell-permeating alpha-ketoglutarate derivatives alleviate pseudohypoxia in succinate dehydrogenase-deficient cells. (2008) (66)
The von Hippel-Lindau tumor suppressor protein: roles in cancer and oxygen sensing. (2005) (65)
Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein. (2006) (65)
New insights into the biology of renal cell carcinoma. (2011) (65)
EGLN1 Inhibition and Rerouting of α-Ketoglutarate Suffice for Remote Ischemic Protection (2016) (63)
Mutation analysis of HIF prolyl hydroxylases (PHD/EGLN) in individuals with features of phaeochromocytoma and renal cell carcinoma susceptibility (2010) (63)
EglN2 associates with the NRF1‐PGC1α complex and controls mitochondrial function in breast cancer (2015) (55)
From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. (2021) (55)
The human p73 promoter: characterization and identification of functional E2F binding sites. (2002) (51)
The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis (2019) (49)
Negative control elements of the cell cycle in human tumors. (1998) (48)
TSC 2 regulates VEGF through mTOR-dependent and-independent pathways (2003) (48)
Using cancer genetics to guide the selection of anticancer drug targets. (2002) (47)
Cancer: Many vessels, faulty gene (1999) (47)
Treatment of erythropoietin deficiency in mice with systemically administered siRNA. (2012) (46)
Inhibition of the oxygen sensor PHD2 in the liver improves survival in lactic acidosis by activating the Cori cycle (2015) (45)
Blood flow to primary tumors and lymph node metastases in SMT-2A tumor-bearing rats following intravenous flunarizine. (1984) (45)
Microwave hyperthermia and its effect on tumor blood flow in rats. (1983) (43)
Targeting HIF2 in Clear Cell Renal Cell Carcinoma. (2016) (42)
The Molecular Basis of Von Hippel-Lindau Disease (1997) (42)
Detection of peptides, proteins, and drugs that selectively interact with protein targets. (2002) (41)
Molecular pathogenesis of the von Hippel-Lindau hereditary cancer syndrome: implications for oxygen sensing. (2001) (40)
Recent insights into the functions of the retinoblastoma susceptibility gene product. (1997) (40)
The von hippel-lindau tumor suppressor protein: an update. (2007) (40)
Innovations and Challenges in Renal Cell Carcinoma: Summary Statement from the Second Cambridge Conference (2007) (39)
VHL and kidney cancer. (2003) (38)
HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species (2019) (37)
Proceedings of the Oxygen Homeostasis/Hypoxia Meeting. (2004) (36)
Gleevec: Prototype or Outlier? (2004) (36)
Skp2 dictates cell cycle-dependent metabolic oscillation between glycolysis and TCA cycle (2020) (36)
Pathways for Oxygen Regulation and Homeostasis: The 2016 Albert Lasker Basic Medical Research Award. (2016) (35)
E2F1 as a target: promoter-driven suicide and small molecule modulators. (2003) (35)
Systemic lupus erythematosus and myelofibrosis. (1986) (34)
Recent insights into the molecular pathogenesis of pheochromocytoma and paraganglioma (2006) (34)
HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase (2017) (34)
Correction: p73 is a human p53-related protein that can induce apoptosis (1999) (33)
Stable binding to E 2 F is not required for the retinoblastoma protein to activate transcription , promote differentiation , and suppress tumor cell growth (1997) (32)
Kidney cancer: now available in a new flavor. (2008) (30)
Publish houses of brick, not mansions of straw (2017) (30)
Genetic evidence of a precisely tuned dysregulation in the hypoxia signaling pathway during oncogenesis. (2014) (30)
xRB as a modulator of transcription (1996) (29)
Peptidic degron for IMiD-induced degradation of heterologous proteins (2019) (28)
Innovations and Challenges in Renal Cancer (2004) (28)
Alterations in G1/S Cell‐Cycle Control Contributing to Carcinogenesis (1997) (27)
Cyclin D1 suppresses retinoblastoma protein-mediated inhibition of TAFII250 kinase activity (2000) (27)
Good COP1 or bad COP1? In vivo veritas. (2011) (27)
Another p53 Doppelgänger? (1998) (26)
The Biological Underpinnings of Namib Desert Fairy Circles (26)
Structure and partial genomic sequence of the human E2F1 gene. (1996) (25)
Erlotinib therapy for central nervous system hemangioblastomatosis associated with von Hippel-Lindau disease: a case report (2010) (24)
Mouse Reporter Strain for Noninvasive Bioluminescent Imaging of Cells that have Undergone Cre-Mediated Recombination (2003) (23)
The Emerging p 53 Gene Family (1999) (22)
Mutant p53 induces a hypoxia transcriptional program in gastric and esophageal adenocarcinoma. (2019) (22)
Faculty Opinions recommendation of Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. (2004) (21)
RB associates with an E2F-like, sequence-specific DNA-binding protein. (1991) (21)
A conserved region of unknown function participates in the recognition of E2F family members by the adenovirus E4 ORF 6/7 protein. (1996) (20)
Innovations and challenges in renal cancer: Summary statement from the Third Cambridge Conference (2009) (19)
Erratum to ‘RB as a modulator of transcription’ [Biochim. Biophys. Acta 1288 (1996) M1–M5]☆ (1996) (19)
BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1α activation (2018) (18)
Peptidic degron in EID1 is recognized by an SCF E3 ligase complex containing the orphan F-box protein FBXO21 (2015) (17)
Fluorescence-activated cell sorting of transfected cells. (1997) (16)
CANCER-RELEVANT CULLIN-RING UBIQUITIN LIGASES (2005) (15)
Erratum: A protein synthesis-dependent increase in E2F1 mRNA correlates with growth regulation of the dihydrofolate reductase promoter (Molecular and Cellular Biology 13:3 (1613)) (1993) (15)
Mitochondrial remodeling and ischemic protection by G protein–coupled receptor 35 agonists (2022) (15)
Differential control of transcription by DNA-bound cyclins. (2001) (15)
Structural and functional contributions to the G1 blocking action of the retinoblastoma protein. (the 1992 Gordon Hamilton Fairley Memorial Lecture). (1993) (15)
RB [corrected] as a modulator of transcription. (1996) (14)
The Human p 73 Promoter : Characterization and Identification of Functional E 2 F Binding Sites 1 (2014) (14)
De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma (2022) (13)
Senescence triggered by the loss of the VHL tumor suppressor (2008) (13)
HIF2 Inhibitor Joins the Kidney Cancer Armamentarium. (2018) (13)
Belzutifan, a Potent HIF2α Inhibitor, in the Pacak-Zhuang Syndrome. (2021) (13)
EglN3 hydroxylase stabilizes BIM-EL linking VHL type 2C mutations to pheochromocytoma pathogenesis and chemotherapy resistance (2019) (13)
Inactivation of the PBRM 1 tumor suppressor gene amplifies the HIF-response in VHL − / − clear cell renal carcinoma (2017) (13)
Targeting oncoproteins with a positive selection assay for protein degraders (2020) (13)
Analysis of von Hippel-Lindau hereditary cancer syndrome: implications of oxygen sensing. (2004) (11)
Bioluminescent imaging of ubiquitin ligase activity: measuring Cdk2 activity in vivo through changes in p27 turnover. (2005) (11)
Transcription of the E2F-1 gene is rendered cell cycle dependent by E2F DNA-binding sites within its promoter (1995) (10)
Autochthonous tumors driven by Rb1 loss have an ongoing requirement for the RBP2 histone demethylase (2018) (10)
The von Hippel–Lindau Tumor Suppressor Protein (2018) (10)
New cancer targets emerging from studies of the Von Hippel-Lindau tumor suppressor protein. (2010) (8)
Slaying RAS with a synthetic lethal weapon (2010) (8)
Taking aim at novel molecular targets in cancer therapy. (1999) (8)
Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. (2022) (7)
Targeting HIF 2 in Clear Cell Renal Cell Carcinoma (2017) (6)
von Hippel–Lindau-associated malignancies: Mechanisms and therapeutic opportunities (2005) (6)
Prostate cancer: beta control your hormones. (2010) (6)
Mutation Selective IDH Inhibitors Mediate Histone and DNA Methylation Changes (2012) (5)
For their discoveries of how cells sense and adapt to oxygen availability (2019) (5)
Cell biology: Divining cancer cell weaknesses (2006) (5)
Sensitivity of VHL mutant kidney cancers to HIF2 inhibitors does not require an intact p53 pathway (2022) (4)
Phosphorylation of ETS 1 by Src Family Kinases Prevents Its Recognition by the COP 1 Tumor Suppressor (2014) (4)
Molecular Biology of Clear Cell Renal Carcinoma (2012) (4)
Enantiomer-Specific Transformation by 2HG Is Linked to Opposing Effects on α-Ketoglutarate-Dependent Dioxygenases (2011) (4)
Cancer Chemotherapy Based on E2F and the Retinoblastoma Pathway (2002) (3)
Leveraging insights into cancer metabolism—a symposium report (2019) (3)
Von Hippel-Lindau Disease: Clinical and Molecular Aspects (2000) (3)
DisABLing kidney cancers caused by fumarate hydratase mutations. (2014) (3)
DDRE-29. DE NOVO PYRIMIDINE SYNTHESIS IS A TARGETABLE VULNERABILITY IN IDH-MUTANT GLIOMA (2021) (3)
Innovations and Challenges in Renal Cancer: Consensus Statement from the First International Conference (2004) (3)
Von Hippel–Lindau disease: insights into oxygen sensing, protein degradation, and cancer (2022) (3)
A Mesenchymal Tumor Cell State Confers Increased Dependency on the BCL-XL Anti-apoptotic Protein in Kidney Cancer (2022) (3)
ACUTE HYPOXIA-INDUCIBLE FACTOR EGLN1 INACTIVATION PROTECTS AGAINST ISCHEMIA-REPERFUSION INJURY BY REGULATION OF GLUCOSE OXIDATION AND REACTIVE OXYGEN SPECIES GENERATION (2013) (2)
Horizontal Transfer of Histone H3 by Mammalian Cells (2021) (2)
39 – Molecular Abnormalities in Kidney Cancer (2015) (2)
Rigor and Reproducibility From a PI’s Perspective (2017) (2)
A Comprehensive Study of the VHL-R200W Chuvash Polycythemia Mutation Reveals a Gradual Dysregulation of the Hypoxia Pathway in Oncogenesis (2014) (2)
Faculty Opinions recommendation of Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. (2002) (2)
Molecular Biology of Kidney Cancer (2012) (2)
Nineteenth Annual Pezcoller Symposium: hypothesis-driven clinical investigation in cancer. (2007) (2)
THE VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN AND KIDNEY CANCER (2007) (1)
Cancer Genetics and Drug Target Selection (2005) (1)
Mutant p 53 induces a hypoxia transcriptional program in gastric and esophageal adenocarcinoma (2019) (1)
TMOD-14. CREATION OF A GENETICALLY ENGINEERED MOUSE MODEL OF ANAPLASTIC ASTROCYTOMA DRIVEN BY THE IDH1-R132H ONCOGENE (2020) (1)
Amendment history : Corrigendum ( October 2009 ) HIF 2 a cooperates with RAS to promote lung tumorigenesis in mice (2018) (1)
Liver Specific Delivery of siRNA Targeting EGLN Prolyl Hydroxylases Activates Hepatic Erythropoietin Production and Stimulates Erythropoiesis (2011) (1)
IDH Mutations, 2-Oxoglutarate-dependent Dioxygenases, and Leukemia (2014) (1)
Abstract C124: HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species (2019) (1)
THE JEREMIAH METZGER LECTURE:VON HIPPEL-LINDAU DISEASE: INSIGHTS INTO OXYGEN SENSING, CANCER AND DRUGGING THE UNDRUGGABLE. (2022) (1)
Selective Killing of Cancer Cells based on Derepression of E2F (1999) (1)
The Molecular Biology of Kidney Cancer and Its Clinical Translation into Treatment Strategies (2009) (1)
Identification of De Novo Pyrimidine Synthesis as a Targetable Vulnerability in a Novel IDH1 Mutant Engineered Astrocytoma Model. (2021) (1)
Loss of CDK4/6 Activity Is Synthetic Lethal with VHL Inactivation in Clear Cell Renal Cell Carcinoma (2019) (1)
Climate Change: What Would Lincoln Do? (2017) (1)
David M. Livingston (1941–2021) (2021) (1)
THE VHL-ELONGINC-ELONGINB STRUCTURE (1999) (1)
1 VHL Tumor Suppressor Gene : Role in VHL Disease and Kidney Cancer (2019) (0)
Publish houses of brick, not mansions of straw (2017) (0)
Faculty Opinions recommendation of RNA interference targeting Fas protects mice from fulminant hepatitis. (2003) (0)
446: Hypoxia Inducible Factor-Independent Function of PVHL and Its Roles on the Development of Familial Pheochromocytoma (2007) (0)
Structure of a HIF-1a-pVHL-ElonginB-ElonginC Complex (2002) (0)
The cancer connection : von Hippel – Lindau disease (2016) (0)
Abstract IA29: Targeting undruggable proteins for degradation with small molecules (2017) (0)
The cdk/pRB/E2F pathway in human cancer (1999) (0)
Author Correction: Skp2 dictates cell cycle-dependent metabolic oscillation between glycolysis and TCA cycle (2020) (0)
Abstract LB-164: IDH mutations and tumorgenicity (2012) (0)
In this issue (2005) (0)
Modulation of Protein Stability: Targeting the VHL Pathway (2009) (0)
TTG-2, a lim-domaine protein with a possible role in protein-protein interaction (2007) (0)
244 Kidney cancer and the von Hippel-Lindau tumor suppressor protein: implications for therapy (2004) (0)
Senator McCain and Our Shared Humanity. (2017) (0)
Faculty Opinions recommendation of A large-scale RNAi screen in human cells identifies new components of the p53 pathway. (2004) (0)
Loss of PHD Prolyl Hydroxylase Activity in Cardiomyocytes Phenocopies Ischemic Cardiomyopathy (2010) (0)
The UTX Tumor Suppressor Directly Senses Oxygen to Control Chromatin and Cell Fate (2019) (0)
Faculty Opinions recommendation of C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. (2001) (0)
Targeting Tumors Driven by VHL or IDH Mutations (2016) (0)
Pharmaceuticals and methods for hypoxiebehandlung and screening procedures for (2002) (0)
Abstract 62: Inhibition ofMen1-deficient tumor growth by inactivation of the Rbp2 histone demethylase (2011) (0)
Abstract IA02: Molecular pathogenesis of IDH mutant cancers and evolving treatment strategies (2015) (0)
A Conversation with William Kaelin. (2016) (0)
Light emitting fusion proteins as well as diagnostic and therapeutic procedures for (2002) (0)
DDRE-32. THERAPEUTIC TARGETING OF A NOVEL METABOLIC ADDICTION IN DIFFUSE MIDLINE GLIOMA (2021) (0)
University of Birmingham Mutation analysis of HIF-prolylhydroxylases (PHD/EGLN) in individuals with features of phaeochromocytoma and renal cell carcinoma susceptibility (2010) (0)
Faculty Opinions recommendation of Selective inhibition of cotranslational translocation of vascular cell adhesion molecule 1. (2005) (0)
Twenty-fifth annual Pezcoller Symposium: Metabolism and tumorigenesis. (2013) (0)
Fifteenth annual Pezcoller symposium: molecular in vivo visualization of cancer cells. (2004) (0)
Transformation by Mutant IDH and ( R )-2HG Is Reversible. (2012) (0)
STEAM GENERATORS OF FORT ST. VRAIN NUCLEAR POWER PLANT, USA. (1970) (0)
The von Hippel-Lindau Tumor Suppressor Gene: Insights into Oxygen Sensing and Cancer (2022) (0)
Meeting Report Third International Meeting on von Hippel-Lindau Disease 1 (2000) (0)
3 Oxygen sensing, HIF hydroxylases and new cancer targets (2009) (0)
Suppression of Tumor Development for Fibronectin Matrix Assembly and pVHL Modification by NEDD8 Is Required (2014) (0)
Abstract 5436: Targeting oncoproteins via disruption of proteostasis: Identification of oncoprotein destabilizing agents using luciferase tagged oncoproteins (2015) (0)
Abstract PL03-02: (Re)emerging principles of cancer therapy (2021) (0)
Disruption of the Ikaros-Mediated Gene Expression Program in Multiple Myeloma with Immunomodulatory Agents (2014) (0)
E2F1 as a Target: Promoter-Driven Suicide and Small Molecule Modulators (2003) (0)
Faculty Opinions recommendation of Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. (2003) (0)
Author Correction: Skp2 dictates cell cycle-dependent metabolic oscillation between glycolysis and TCA cycle (2020) (0)
Minireviews THE MOLECULAR BASIS OF VON HIPPEL-LINDAU DISEASE (2007) (0)
Skp2 dictates cell cycle-dependent metabolic oscillation between glycolysis and TCA cycle (2020) (0)
The von Hippel-Lindau protein: insights into hypoxic signaling and cancer (2008) (0)
Abstract 16056: Acute HIF Prolyl Hydroxylase 2 Inactivation Confers Protection Against Myocardial Ischemic Reperfusion Injury (2011) (0)

This paper list is powered by the following services:

Other Resources About William Kaelin Jr.

en.wikipedia.org

What Schools Are Affiliated With William Kaelin Jr.?

William Kaelin Jr. is affiliated with the following schools:

William Kaelin Jr.'s Academic­Influence.com Rankings